目的：以光学相干断层扫描血管成像(optical coherence tomography angiography，OCTA)评价玻璃体腔注射康柏西普治疗湿性年龄相关性黄斑变性(wet age-related macular degeneration，wAMD)的临床疗效。

方法：收集芜湖市眼科医院2016-12/2017-11收治的18例20眼确诊为wAMD的患者，给予玻璃体腔注射康柏西普注射治疗，随访记录治疗1mo后最佳矫正视力(best corrected visual acuity，BCVA)，OCTA检查视网膜黄斑中心凹厚度(foveal macular thickness，FMT)、黄斑中心凹旁厚度(parafoveal macular thickness，PMT)、脉络膜新生血管(choroidal neovascularization，CNV)面积，以及中心凹和中心凹旁浅层血管密度。比较治疗前后各指标的变化。

结果：患者18例20眼经玻璃体腔注射康柏西普治疗1mo后，平均BCVA较术前提高，差异有统计学意义(P<0.05)，平均FMT、PMT、CNV面积及中心凹浅层血流密度与治疗前相比明显下降，差异有统计学意义(P<0.05)，中心凹旁浅层血流密度较术前减少，但差异无统计学意义(P>0.05)。

结论：玻璃体腔注射康柏西普治疗wAMD是安全有效的，同时发现玻璃体腔注射康柏西普能改变视网膜脉络膜自身血管结构。OCTA用于评价康柏西普治疗wAMD的临床疗效更安全，更客观。

METHODS: The retrospective review included 18 patients(20 eyes)which were diagnosed with wAMD in Wuhu Ophthalmic Hospital from December 2016 to November 2017. All affected eyes were injected by conbercept, examined for the best corrected visual acuity(BCVA)and OCTA examine the foveal macular thickness(FMT), parafoveal macular thickness(PMT), choroidal neovascularization(CNV)flow area, foveal superficial vascular plexus flow density and parafoveal superficial vascular plexus flow density. The paired t test was used to compare those before and after treatment.

RESULTS: One months after treatment, the mean BCVA were improved with significant difference(P<0. 05). And the mean FMT, PMT, CNV flow area and foveal superficial vascular plexus flow density significantly decreased with significant difference(P<0.05), and the mean parafoveal superficial vascular plexus flow density decreased but with no statistical significance(P>0.05).

CONCLUSION: This study confirmed that the intravitreal injection of conbercept for treating wAMD is safe and effective. Intravitreal conbercept injections are associated with a significant change in native retinal and choroidal vasculature. OCTA could evaluate the effection of intravitreal injection of conbercept for wAMD more safely, objectively and conveniencely.